The Impact of Unblind Failure of New Drug on Stock Performances of Biotechnology Pharmacy Industry
碩士 === 國立成功大學 === 企業管理學系碩士在職專班 === 105 === The new drug R＆D process must pass through unblind test of clinical tests in phase III, but unblind results of new drugs often make public investors disappointed. New drugs’ unblind failure not only causes a great challenge to companies’ stocks, but also gr...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2017
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/79zsah |